Skip to main content
. Author manuscript; available in PMC: 2016 Jan 8.
Published in final edited form as: Cancer J. 2014 Jan-Feb;20(1):18–24. doi: 10.1097/PPO.0000000000000024

Figure 2.

Figure 2

Examples of skin toxicities experienced by patients treated with vemurafenib. A shows a patient with a maculopapular rash, which developed approximately 3 weeks after initiation of vemurafenib therapy. B shows squamous cell carcinoma of the skin, which was detected 4 to 6 weeks after initiation of vemurafenib therapy. C shows a case of hand-foot skin reaction with hyperkeratosis, which was also reported as palmar-plantar erythrodysesthesia syndrome.